Key Highlights
- A fall of 8.65% puts the indicated price at USD 1.32 on November 18, 2026, against a calculated prior close of USD 1.4450, a calculated move of negative USD 0.1250.
- Revenue for the six months to March 31, 2026 slid 47% to RMB 9.6 million, and the Business moved from a RMB 3.6 million loss to a RMB 0.5 million profit.
- Net income reached RMB 4.8 million, although non-operating items worth RMB 11.8 million, among them a RMB 6.1 million Credit loss reversal, explain most of that profit.
- A bid price deadline of November 23, 2026 is cited, following a Nasdaq deficiency letter received on November 28, 2025, and the company may pursue a reverse split.
Ping An Biomedical (NASDAQ:PASW) Eases to USD 1.32 Ahead of the Session
Ping An Biomedical is priced at USD 1.32 in early trading on Wednesday, November 18, 2026, a decline of 8.65% before the regular session opens. Dividing that price by 0.9135 gives a calculated prior close of USD 1.4450 from the November 17 session, so the move equals negative USD 0.1250 a share. Published figures on Market Value and share count for Ping An Biomedical disagreed between sources, so this article does not rely on either. The indication for Ping An Biomedical therefore rests only on the figures cited here.
No Fresh Catalyst, but a Nasdaq Bid Deadline Looms at Ping An Biomedical
Neither a company release nor a filing dated November 18, 2026 turned up in published coverage that could explain the slide. Low-priced shares of small listed businesses frequently react to thin Liquidity and to sentiment around listing deadlines. A Nasdaq notice about the minimum bid price was issued on November 28, 2025, and coverage then points to a November 23, 2026 compliance date, with a Reverse Stock Split as one possible remedy. Over the six months to March 31, 2026, sales shrank to RMB 9.6 million from RMB 18.23 million, yet the Bottom Line of RMB 4.8 million was buoyed by RMB 11.8 million of non-operating items. Ping An Biomedical reported those results as the backdrop for the stock.
Thin Cash Cushion and Concentrated Revenue at Ping An Biomedical
Operations centre on textile and garment trading, a business that is shrinking as management tilts toward Equity investments. Cash and bank balances totalled RMB 35.9 million, but RMB 29.1 million of that, or 81%, was restricted, while the equity portfolio carried a value of RMB 41.2 million. Customer concentration at Ping An Biomedical is steep: the top three buyers supplied 70% of revenue, and one vendor took 54% of purchases. Ping An Biomedical earned its profit from non-cash items instead of the core trade, so listing compliance, possible dilution from a reverse split and swings in the Investment portfolio are the principal dangers.
Where Things Stand
Yes, the stock is lower before the open: Ping An Biomedical is indicated at USD 1.32, and against a calculated prior close of USD 1.4450 that is an 8.65% drop. No catalyst dated today appears in published coverage. Recent figures show sales falling 47% to RMB 9.6 million, and the RMB 4.8 million net result leaned on RMB 11.8 million of non-operating items. Restricted funds of RMB 29.1 million sit inside RMB 35.9 million of cash, and a compliance date of November 23, 2026 is cited for the bid price. The bid-price question remains the main item to watch, and this text is informational rather than investment advice.



Please wait processing your request...